AI-Based Molecular and Immunological Profiling and Bioanalysis Simplify Drug Development and Advance Precision Medicine for Cancer Patients
TOKYO & WALTHAM, Mass. – (BUSINESS WIRE) – BostonGene, a leading provider of AI-based molecular and immunoassay solutions, and NEC Corporation (NEC; TSE: 6701 ), a leader in IT, networking, and AI technologies ), and Japan Industrial Partners, a leading Tokyo-based private equity firm, today announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture to advance personalized medicine and dramatically improve patient outcomes. The new company will leverage BostonGene’s high-complexity molecular technology and advanced biocomputing algorithms, including the BostonGene Tumor Portrait™ test, to accelerate the development and validation of novel precision medicine approaches.
BostonGene’s AI-driven cloud-based solutions, bioinformatics capabilities, analytical tools, and advanced next-generation molecular and immunological assays can provide a comprehensive view of cancer patients at the molecular level and identify actionable targets for evidence-based treatment decisions. In addition, BostonGene leverages its solutions platform to provide biopharmaceutical customers with a broad range of services, including biomarker discovery, clinical trial testing, assay design and development, and companion diagnostics.
Cancer is responsible for one in four deaths in Japan, with recent figures showing a steady increase in the death rate, data show
. By equipping cancer care centers with BostonGene solutions, more patients will be able to benefit from genomic testing and personalized treatment. Additionally, Japanese researchers and biopharmaceutical companies will benefit from biomarker-driven therapeutic development by leveraging BostonGene industry solutions.“
We look forward to introducing BostonGene solutions to the Japanese market. Our in-depth molecular and immunological analysis and biocomputing capabilities dramatically improve patient outcomes and therapeutic development. Andrew Feinberg, President and CEO of BostonGene, said: “Our solution has been widely adopted in the United States, and we firmly believe that our solution will significantly improve the standard of cancer care in Japan by enabling personalized treatment and improving treatment development.”“
NEC is actively promoting the growth of its healthcare and life science business, centered on its hospital DX business, which has a strong customer base. By partnering with NEC’s healthcare solutions (which leverage powerful AI/digital technologies), we expect BostonGene’s solutions to transform cancer care in Japan and help Japanese pharmaceutical companies develop the most effective therapies. said Takayuki Morita, President and CEO of NEC Corporation.“
JIP is pleased to support NEC’s efforts to create a healthcare and life sciences business utilizing BostonGene’s technology,” said Hidemi Moue, CEO of Japan Industrial Partners.notes
Cancer Research Promotion Foundation, “Cancer Statistics in Japan – 2023”, p. 40 (pdf p. 42). Retrieved from (https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2023.pdf)
About Boston Genetics
BostonGene’s mission is to advance healthcare’s transition to personalized medicine using our AI-based molecular and immune assays to improve standards of care, accelerate research and reduce the overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to multiple therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s test generates a personalized roadmap for each cancer patient’s treatment decisions. For more information, visit BostonGene at: http://www.BostonGene.com.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies, while promoting the brand statement of “curating a brighter world.” NEC enables businesses and communities to adapt to the rapid changes taking place in society and markets as it delivers social values of safety, security, equity and efficiency to promote a more sustainable world where everyone has the opportunity to realize their full potential. For more information, please visit NEC: https://www.nec.com.
About Japan Industry Partners Inc.
Japan Industrial Partners (JIP) is a Tokyo, Japan-based private equity firm specializing in spin-off investments in Japan. JIP provides funding and solutions to businesses with significant room for improvement and growth opportunities.
Source link content provided by Business Wire. Jinri Toutiao is not responsible for the content provided or any link related to the content. Toutiao is not responsible for the correctness, topicality or quality of the content.